Merger Notification - Announcement according to § 10 Cartel Act
PerkinElmer Inc.; BioLegend Inc.
BWB/Z-5606
On 06.08.2021 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
PerkinElmer, Inc., Waltham, Massachusetts, United States of America, intends to acquire 100% of the shares and sole control in BioLegend, Inc., San Diego, California, United States of America. The targets develops, manufactures and commercialises antibodies and related conjugated reagents for biomedical research.
Affected industry: manufacture of basic pharmaceutical products and pharmaceutical preparations
Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 03.09.2021.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 06.09.2021 .